The present invention is concerned with aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives of formula I
wherein
R
1
, R
2
, R
3
, R
4
, and R
5
are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. The invention also relates to methods for preparing such compounds. This class of compounds has a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease. Thus, the invention also is concerned with pharmaceutical compositions containing compounds of formula I or their pharmaceutically acceptable acid addition salts and methods for the treatment of GABA A α5 mediated diseases, including Alzheimer's disease.
本发明涉及式I的芳基
异噁唑-4-羰基
吲哚羧酸酰胺衍
生物,其中R1、R2、R3、R4和R5如规范和权利要求中所定义,并且其药学上可接受的酸加成盐。本发明还涉及制备这种化合物的方法。这类化合物对
GABA A α5受体结合位点具有高亲和力和选择性,可能有助于认知增强或治疗像阿尔茨海默病这样的认知障碍。因此,本发明还涉及含有式I化合物或其药学上可接受的酸加成盐的制药组合物以及治疗
GABA A α5介导疾病,包括阿尔茨海默病的方法。